Aliases & Classifications for Candida Glabrata

MalaCards integrated aliases for Candida Glabrata:

Name: Candida Glabrata 50

Classifications:



Summaries for Candida Glabrata

MalaCards based summary : Candida Glabrata is related to cutaneous candidiasis and primary systemic mycosis. An important gene associated with Candida Glabrata is CSF2 (Colony Stimulating Factor 2), and among its related pathways/superpathways are Th2 Differentiation Pathway and IL-15 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types. The drugs Caspofungin and Micafungin have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and neutrophil, and related phenotypes are immune system and mortality/aging

Wikipedia : 72 Cryptococcus glabratus H.W.Anderson (1917)Torulopsis glabrata (H.W.Anderson) Lodder & N.F.de Vries... more...

Related Diseases for Candida Glabrata

Diseases related to Candida Glabrata via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
id Related Disease Score Top Affiliating Genes
1 cutaneous candidiasis 30.0 CSF2 IFNG
2 primary systemic mycosis 10.4 CSF2 IFNG
3 optic nerve neoplasm 10.4 CSF2 IFNG
4 hunter macpherson syndrome 10.4 CSF2 IFNG
5 candidiasis 10.3
6 pasteurellosis 10.3 CSF2 IFNG
7 vaginitis 10.3
8 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.3 CSF2 IFNG
9 vulvovaginitis 10.2
10 renal tubular acidosis 10.2 CSF2 IFNG
11 vulvovaginal candidiasis 10.1
12 endocarditis 10.1
13 endophthalmitis 10.1
14 chorioamnionitis 10.0
15 osteomyelitis 10.0
16 pneumonia 10.0
17 endotheliitis 10.0
18 keratitis 9.9
19 hematopoietic stem cell transplantation 9.9
20 esophagitis 9.9
21 cholecystitis 9.9
22 peritonitis 9.9
23 acute interstitial pneumonia 9.9 DHFR IFNG
24 sclerosing cholangitis 9.7 HTN3 SKAP2
25 arthritis 9.7
26 chronic granulomatous disease 9.7
27 leukemia 9.7
28 spinal cord injury 9.7
29 aspiration pneumonia 9.7
30 infective endocarditis 9.7
31 colitis 9.7
32 mucositis 9.7
33 malignant otitis externa 9.7
34 epidural abscess 9.7
35 heart disease 9.7
36 constrictive pericarditis 9.7
37 nephrotic syndrome 9.7
38 denture stomatitis 9.7
39 neurogenic bladder 9.7
40 olecranon bursitis 9.7
41 cystitis 9.7
42 pericarditis 9.7
43 orchitis 9.7
44 bursitis 9.7
45 thrombophlebitis 9.7
46 myocarditis 9.7
47 myeloid leukemia 9.7
48 chorioretinitis 9.7
49 epididymo-orchitis 9.7
50 otitis externa 9.7

Graphical network of the top 20 diseases related to Candida Glabrata:



Diseases related to Candida Glabrata

Symptoms & Phenotypes for Candida Glabrata

MGI Mouse Phenotypes related to Candida Glabrata:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.5 RBPJ RIF1 SKAP2 SQLE APCS CSF2
2 mortality/aging MP:0010768 9.28 IFNG LSS RBPJ RIF1 SKAP2 SQLE

Drugs & Therapeutics for Candida Glabrata

Drugs for Candida Glabrata (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 468682 2826718
2
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
5
Fluconazole Approved Phase 4 86386-73-4 3365
6
Voriconazole Approved, Investigational Phase 4 137234-62-9 71616
7 Antifungal Agents Phase 4
8 Anti-Infective Agents Phase 4
9 Echinocandins Phase 4
10 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
11 Cytochrome P-450 CYP3A Inhibitors Phase 4
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Hormone Antagonists Phase 4
14 Hormones Phase 4
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
16 Steroid Synthesis Inhibitors Phase 4
17
Mechlorethamine Approved 51-75-2 4033
18 Anti-Infective Agents, Local
19 chloramine-T
20 Disinfectants
21 Eusol
22 Pharmaceutical Solutions
23 Sodium hypochlorite
24 Castor Nutraceutical
25 Brewer's Yeast Nutraceutical

Interventional clinical trials:


id Name Status NCT ID Phase Drugs
1 Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins Completed NCT00839540 Phase 4 micafungin;Micafungin;Caspofungin
2 Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis Completed NCT00496197 Phase 4 Eraxis (anidulafungin);Diflucan (fluconazole);Vfend (voriconazole)
3 Clinical Conditions and Prevalence of Periodontopathogens in Smokers and Non-smokers After Periodontal Therapy Unknown status NCT02581319
4 Clinical and Laboratorial Evaluation of the Desinfection Solutions in Candida Species From Total Prostheses and Palate of Total Edentulous. Completed NCT03203551
5 Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis Recruiting NCT02859493

Search NIH Clinical Center for Candida Glabrata

Genetic Tests for Candida Glabrata

Anatomical Context for Candida Glabrata

MalaCards organs/tissues related to Candida Glabrata:

39
Testes, Colon, Neutrophil, Monocytes, Endothelial, Myeloid, Nk Cells

Publications for Candida Glabrata

Articles related to Candida Glabrata:

(show top 50) (show all 642)
id Title Authors Year
1
Dectin-1 plays an important role in host defense against systemic Candida glabrata infection. ( 28658592 )
2017
2
The CgHaa1-Regulon Mediates Response and Tolerance to Acetic Acid Stress in the Human Pathogen Candida glabrata. ( 27815348 )
2017
3
Quantification of CDR1 Gene Expression in Fluconazole Resistant Candida Glabrata Strains Using Real-time PCR. ( 28894714 )
2017
4
Enantioselective bioreduction of benzo-fused cyclic ketones with engineered Candida glabrata ketoreductase 1 - a promising synthetic route to ladostigil (TV3326). ( 28848953 )
2017
5
Comparative Genomics of Two Sequential Candida glabrata Clinical Isolates. ( 28663342 )
2017
6
Relationship between the Antifungal Susceptibility Profile and the Production of Virulence-Related Hydrolytic Enzymes in Brazilian Clinical Strains of Candida glabrata. ( 28814823 )
2017
7
Differentiation of Candida albicans, Candida glabrata, and Candida krusei by FT-IR and chemometrics by CHROMagara8c Candida. ( 28822772 )
2017
8
Dectin-1 embraces Candida glabrata. ( 28727942 )
2017
9
Potential Use of MALDI-ToF Mass Spectrometry for Rapid Detection of Antifungal Resistance in the Human Pathogen Candida glabrata. ( 28831086 )
2017
10
CgMED3 Changes Membrane Sterol Composition To Help Candida glabrata Tolerate Low-pH Stress. ( 28667115 )
2017
11
Galleria mellonella as a host model to study Candida glabrata virulence and antifungal efficacy. ( 28658597 )
2017
12
Unexpected effects of azole transporter inhibitors on antifungal susceptibility in Candida glabrata and other pathogenic Candida species. ( 28700656 )
2017
13
In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates. ( 27872063 )
2017
14
Fungicidal effect of thymoquinone involves generation of oxidative stress in Candida glabrata. ( 28024529 )
2017
15
The Fungal Pathogen Candida glabrata Does Not Depend on Surface Ferric Reductases for Iron Acquisition. ( 28642757 )
2017
16
Emergence of Candida glabrata in vulvovaginal candidiasis should be attributed to selective pressure or virulence ability? ( 28730269 )
2017
17
De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance. ( 28630180 )
2017
18
Fungicidal activity of copper-sputtered flexible surfaces under dark and actinic light against azole-resistant Candida albicans and Candida glabrata. ( 28802173 )
2017
19
Functional analysis of selected deletion mutants in Candida glabrata under hypoxia. ( 28664376 )
2017
20
Repeated applications of photodynamic therapy on Candida glabrata biofilms formed in acrylic resin polymerized. ( 28091850 )
2017
21
Med15B Regulates Acid Stress Response and Tolerance in Candida glabrata by Altering Membrane Lipid Composition. ( 28710262 )
2017
22
Lumbar Spinal Candida Glabrata Treated Without Surgical Intervention: A Case Report. ( 28744418 )
2017
23
Genome mining, in silico validation and phase selection of a novel aldo-keto reductase from Candida glabrata for biotransformation. ( 28644714 )
2017
24
Crz1p regulates pH homeostasis in Candida glabrata by altering membrane lipid composition. ( 27663025 )
2016
25
Multiplex PCR designed to differentiate species within the Candida glabrata complex. ( 27810263 )
2016
26
Candida glabrata among Candida spp. from environmental health practitioners of a Brazilian Hospital. ( 26991302 )
2016
27
Time-to-reporting of blood culture positivity and central venous catheter-associated Candida glabrata fungemia in cancer patients. ( 27133559 )
2016
28
Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria. ( 26806376 )
2016
29
Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia. ( 27484020 )
2016
30
A Network of Paralogous Stress Response Transcription Factors in the Human Pathogen Candida glabrata. ( 27242683 )
2016
31
The multidrug resistance transporters CgTpo1_1 and CgTpo1_2 play a role in virulence and biofilm formation in the human pathogen Candida glabrata. ( 27780306 )
2016
32
Candida species isolated from different body sites and their antifungal susceptibility pattern: Cross-analysis of Candida albicans and Candida glabrata biofilms. ( 27915303 )
2016
33
Fungal CYP51 Inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. ( 27956419 )
2016
34
Current trends in candidemia and species distribution among adults: Candida glabrata surpasses C. albicans in diabetic patients and abdominal sources. ( 27402377 )
2016
35
A Murine Model of Candida glabrata Vaginitis Shows No Evidence of an Inflammatory Immunopathogenic Response. ( 26807975 )
2016
36
Effects of Aspirin as an Anti-inflammatory Drug on Azole-resistant Candida glabrata In Vitro. ( 28028508 )
2016
37
Candida glabrata encodes a longer variant of the mating type (MAT) alpha2 gene in the mating type-like MTL3 locus, which can form homodimers. ( 27650705 )
2016
38
Clotrimazole Drug Resistance in Candida glabrata Clinical Isolates Correlates with Increased Expression of the Drug:H(+) Antiporters CgAqr1, CgTpo1_1, CgTpo3, and CgQdr2. ( 27148215 )
2016
39
Multilocus microsatellite analysis of European and African Candida glabrata isolates. ( 26946511 )
2016
40
Candida glabrata survives and replicates in human osteoblasts. ( 27073253 )
2016
41
Genome engineering in the yeast pathogen Candida glabrata using the CRISPR-Cas9 system. ( 27767081 )
2016
42
Upregulation of the Adhesin Gene EPA1 Mediated by PDR1 in Candida glabrata Leads to Enhanced Host Colonization. ( 27303714 )
2016
43
Identification of Genes in Candida glabrata Conferring Altered Responses to Caspofungin, a Cell Wall Synthesis Inhibitor. ( 27449515 )
2016
44
Roles of vacuolar H+-ATPase in the oxidative stress response of Candida glabrata. ( 27370212 )
2016
45
In vitro Synergistic Activity of Caspofungin Plus Polymyxin B Against Fluconazole-Resistant Candida glabrata. ( 26992255 )
2016
46
Interaction of human fibronectin with Candida glabrata epithelial adhesin 6 (Epa6). ( 27474404 )
2016
47
Iron-depletion promotes mitophagy to maintain mitochondrial integrity in pathogenic yeast Candida glabrata. ( 27347716 )
2016
48
Fluconazole and Echinocandin Resistance of Candida glabrata Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance. ( 28066361 )
2016
49
KRE5 Suppression Induces Cell Wall Stress and Alternative ER Stress Response Required for Maintaining Cell Wall Integrity in Candida glabrata. ( 27548283 )
2016
50
Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata. ( 26976780 )
2016

Variations for Candida Glabrata

Expression for Candida Glabrata

Search GEO for disease gene expression data for Candida Glabrata.

Pathways for Candida Glabrata

Pathways related to Candida Glabrata according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.83 IFNG RBPJ
2
Show member pathways
10.56 CSF2 IFNG
3 10.1 CSF2 IFNG

GO Terms for Candida Glabrata

Biological processes related to Candida Glabrata according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cholesterol biosynthetic process GO:0006695 9.43 LSS SQLE
2 killing of cells of other organism GO:0031640 9.4 HTN1 HTN3
3 biomineral tissue development GO:0031214 9.37 HTN1 HTN3
4 regulation of cholesterol biosynthetic process GO:0045540 9.32 LSS SQLE
5 defense response to fungus GO:0050832 9.26 HTN1 HTN3
6 defense response to bacterium GO:0042742 9.26 HTN1 HTN3 IFNG RBPJ
7 myeloid dendritic cell differentiation GO:0043011 9.16 CSF2 RBPJ
8 positive regulation of interleukin-23 production GO:0032747 8.62 CSF2 IFNG

Sources for Candida Glabrata

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....